Related references
Note: Only part of the references are listed.BET bromodomain inhibitors: a patent review
Jean-Marc Garnier et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Discovery of BET bromodomain inhibitors and their role in target validation
S. Mueller et al.
MEDCHEMCOMM (2014)
Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain
Lele Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Lewis R. Vidler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
David S. Hewings et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
Shwu-Yuan Wu et al.
MOLECULAR CELL (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Sarah Picaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Small-Molecule Inhibition of BRDT for Male Contraception
Martin M. Matzuk et al.
CELL (2012)
The bromodomain interaction module
Panagis Filippakopoulos et al.
FEBS LETTERS (2012)
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Lewis R. Vidler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery
Chun-wa Chung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides
Paul Bamborough et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit
Paul V. Fish et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Place your BETs: the therapeutic potential of bromodomains
R. K. Prinjha et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Inhibition of bromodomain-mediated protein-protein interactions as a novel therapeutic strategy
Silviya D. Furdas et al.
MEDCHEMCOMM (2012)
Bromodomains: Are Readers Right for Epigenetic Therapy?
Stuart J. Conway
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Bromodomains as therapeutic targets
Susanne Muller et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
Discovery and Characterizatlion of Small Molecule Inhibitors of the BET Family Bromodomains
Chun-wa Chung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Brd2 disruption in mice causes severe obesity without Type 2 diabetes
Fangnian Wang et al.
BIOCHEMICAL JOURNAL (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists
Christian Laurence et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene (NHC)-Pd precatalysts, PEPPSI
Michael G. Organ et al.
CHEMISTRY-A EUROPEAN JOURNAL (2008)
Lysine acetylation and the bromodomain: a new partnership for signaling
XJ Yang
BIOESSAYS (2004)
Acetylation: a regulatory modification to rival phosphorylation?
T Kouzarides
EMBO JOURNAL (2000)
Share Paper
